Processing

Please wait...

Settings

Settings

Goto Application

Offices all Languages Stemming false Single Family Member true

Save query

A private query is only visible to you when you are logged-in and can not be used in RSS feeds

Query Tree

Refine Options

Offices
All
Specify the language of your search keywords
Stemming reduces inflected words to their stem or root form.
For example the words fishing, fished,fish, and fisher are reduced to the root word,fish,
so a search for fisher returns all the different variations
Returns only one member of a family of patents

Full Query

IC_EX:A61K39/395

Side-by-side view shortcuts

General
Go to Search input
CTRL + SHIFT +
Go to Results (selected record)
CTRL + SHIFT +
Go to Detail (selected tab)
CTRL + SHIFT +
Go to Next page
CTRL +
Go to Previous page
CTRL +
Results (First, do 'Go to Results')
Go to Next record / image
/
Go to Previous record / image
/
Scroll Up
Page Up
Scroll Down
Page Down
Scroll to Top
CTRL + Home
Scroll to Bottom
CTRL + End
Detail (First, do 'Go to Detail')
Go to Next tab
Go to Previous tab

Analysis

1.WO/2021/011377METHODS OF ENHANCING IMMUNOGENICITY OF CANCERS
WO 21.01.2021
Int.Class A61K 39/395
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
Appl.No PCT/US2020/041603 Applicant THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY Inventor BERTOZZI, Carolyn
Provided are methods of enhancing immunogenicity of cancers. In certain aspects, the methods include administering an effective amount of a sialic acid modulator to an individual identified as having a cancer comprising dysregulated Myc. According to some aspects, the methods include administering an effective amount of a disialyl-T modulator to an individual identified as having a cancer comprising cell surface expression of disialyl-T. In certain aspects, the methods include administering an effective amount of an agent to an individual identified as having a cancer comprising cell surface expression of a glycoprotein comprising an O-glycosylated mucin-like domain, where the agent modulates the glycoprotein. Also provided are methods of assessing whether a cancer of an individual comprises dysregulated Myc.
2.WO/2021/010326ANTI-MUTATION TYPE FGFR3 ANTIBODY AND USE THEREFOR
WO 21.01.2021
Int.Class A61K 39/395
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
Appl.No PCT/JP2020/027043 Applicant CHUGAI SEIYAKU KABUSHIKI KAISHA Inventor KAMIKAWAJI, Shogo
The present invention provides an antibody that makes it possible to distinguish between wild FGFR3 and S249C mutation-type FGFR3. In addition, an antigen-binding molecule that makes it possible to selectively damage tumor cells expressing S249C mutation-type FGFR3 was built using the antibody.
3.WO/2021/009020EXCIPIENT FOR BIOTHERAPEUTICS
WO 21.01.2021
Int.Class A61K 9/08
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
9Medicinal preparations characterised by special physical form
08Solutions
Appl.No PCT/EP2020/069494 Applicant LUDWIG-MAXIMILIANS-UNIVERSITÄT MÜNCHEN Inventor WINTER, Gerhard
The present invention relates to excipients for stabilizing active agents, in particular peptides, polypeptides, nucleic acids, viruses, virus-like particles, proton pump inhibitors and antibiotics. The excipient reduces aggregate and/or particle formation in preparations comprising said agents. The excipient is a diamide of a dicarboxylic acid comprising at least one N-H amido group, at least one unsubstituted or substituted N-hydroxyethylamido group and/or at least one unsubstituted N-hydroxymethylamido group. In particular, the excipient is N,N,N',N'-tetrakis-(2-hydroxyethyl) adipinic acid amide.
4.WO/2021/009740COMPOSITIONS AND METHODS FOR THE TREATMENT OF TUBERCULOSIS
WO 21.01.2021
Int.Class G01N 33/569
GPHYSICS
01MEASURING; TESTING
NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
33Investigating or analysing materials by specific methods not covered by groups G01N1/-G01N31/131
48Biological material, e.g. blood, urine; Haemocytometers
50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
53Immunoassay; Biospecific binding assay; Materials therefor
569for microorganisms, e.g. protozoa, bacteria, viruses
Appl.No PCT/IL2019/050801 Applicant RAMOT AT TEL-AVIV UNIVERSITY LTD. Inventor FREUND, Natalia
A human antibody comprising an antigen binding domain which binds Pst S1 of Mycobacterium tuberculosis (TB) for use in preventing or treating TB infection in a subject in need thereof is provided. Also provided are vaccine compositions and conjugates of such antibodies.
5.WO/2021/009950AGENT FOR ENHANCING EFFECT OF ANTICANCER AGENT
WO 21.01.2021
Int.Class A61K 39/395
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
Appl.No PCT/JP2020/004226 Applicant DELTA-FLY PHARMA, INC. Inventor WADA Hiromi
The present invention relates to a pharmaceutical composition that contains a citrate used to enhance the effect of an anticancer agent.
6.WO/2021/011660METHODS AND COMPOSITIONS FOR DETECTION AND TREATMENT OF LUNG CANCER
WO 21.01.2021
Int.Class A61K 39/395
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
Appl.No PCT/US2020/042146 Applicant ONCOCYTE CORPORATION Inventor HESTERBERG, Lyndal, K.
Disclosed herein are methods for detecting whether a subject is at risk of lung cancer based on a blood-based multivariate gene expression classifier. Methods for determining whether to obtain a biopsy in a subject based on a blood-based multivariate gene expression classifier are also disclosed. Further disclosed are methods for treating lung cancer based on a blood-based multivariate gene expression classifier are disclosed. Kits for detecting the expression levels of biomarkers for determining whether a subject is at risk of lung cancer are also disclosed.
7.WO/2021/011885CLAUDIN18 ANTIBODIES AND METHODS OF TREATING CANCER
WO 21.01.2021
Int.Class C07K 16/30
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins, e.g. monoclonal or polyclonal antibodies
18against material from animals or humans
28against receptors, cell surface antigens or cell surface determinants
30from tumour cells
Appl.No PCT/US2020/042573 Applicant THE REGENTS OF THE UNIVERSITY OF CALIFORNIA Inventor CONKLIN, Dylan
The present disclosure provides antigen-binding proteins which bind to Claudin- 18.2 (CLDN18.2); bispecific antigen-binding proteins which bind to CLDN18.2 and a second antigen; and conjugates thereof. In various aspects, the antigen-binding proteins bind to Extracellular Loop 1 (ELI) of the extracellular domain of CLDN18.2. Related polypeptides, nucleic acids, vectors, host cells, and conjugates are further provided herein. Kits and pharmaceutical compositions comprising such entities are moreover provided. Also provided are methods of making an antigen-binding protein and methods of treating a subject having cancer.
8.WO/2021/009694FUNCTIONAL BINDERS SYNTHESIZED AND SECRETED BY IMMUNE CELLS
WO 21.01.2021
Int.Class A61K 35/17
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
35Medicinal preparations containing materials or reaction products thereof with undetermined constitution
12Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
14Blood; Artificial blood
17Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
Appl.No PCT/IB2020/056659 Applicant NATIONAL UNIVERSITY OF SINGAPORE Inventor SHIMASAKI, Noriko
The invention relates to an in vivo functional ligands (IFLs) including a single-chain variable fragment (scFv) domain, a fragment crystalIizable (Fc) domain, and a hinge domain joining the scFv and Fc domains. The IFLs specifically bind target receptors and are capable of triggering antibody-dependent cell cytotoxicity (ADCC), antibody-dependent cell phagocytosis (ADCP) and complement-dependent cytotoxicity (CDC), as well as cytokine stimulation. The IFLs may be joined to a chimeric antigen receptor via a self-cleaving peptide. The IFLs may be expressed in immune cells, such as a natural killer cell or a T lymphocyte. Vectors, host cells, and methods of making IFLs are also described.
9.WO/2021/011404THERAPEUTIC PROTEIN FORMULATIONS COMPRISING ANTIBODIES AND USES THEREOF
WO 21.01.2021
Int.Class A61K 39/00
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
Appl.No PCT/US2020/041687 Applicant CONTRAFECT CORPORATION Inventor THARIATH, Abraham
The present disclosure is directed to an aqueous therapeutic protein formulation including: (i) one or more therapeutic proteins, wherein the one or more therapeutic proteins include one or more anti-influenza antibodies or antigen-binding fragments thereof in an amount ranging from 30 to 150 mg/mL; (ii) histidine buffer, (iii) NaCl, and (iv) an aqueous carrier, wherein a pH of the aqueous therapeutic formulation ranges from 5.5-8.0, and wherein the formulation is formulated for respiratory tract delivery and produces particles including the one or more therapeutic proteins upon aerosolization. Methods of generating an aerosol and treating influenza are also provided.
10.WO/2021/011614METHODS FOR TREATING OR PREVENTING ASTHMA BY ADMINISTERING AN IL-4R ANTAGONIST
WO 21.01.2021
Int.Class A61K 39/395
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
Appl.No PCT/US2020/042075 Applicant SANOFI BIOTECHNOLOGY Inventor STAUDINGER, Heribert
Methods for treating or preventing asthma (e.g., allergic asthma, asthma associated with allergic bronchopulmonary aspergillosis (ABPA), moderate-to-severe asthma, persistent asthma or the like) and associated conditions (e.g., ABPA, ABPA comorbid with asthma, ABPA comorbid with cystic fibrosis (CF), ABPA comorbid with asthma and CF) in a subject are provided. Methods comprising administering to a subject in need thereof a therapeutic composition comprising an interleukin-4 receptor (IL-4R) antagonist, such as an anti-IL-4R antibody or antigen-binding fragment thereof, are provided.